JP2015506174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506174A5 JP2015506174A5 JP2014551569A JP2014551569A JP2015506174A5 JP 2015506174 A5 JP2015506174 A5 JP 2015506174A5 JP 2014551569 A JP2014551569 A JP 2014551569A JP 2014551569 A JP2014551569 A JP 2014551569A JP 2015506174 A5 JP2015506174 A5 JP 2015506174A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- seq
- acid molecule
- molecule according
- cgrp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 63
- 102000039446 nucleic acids Human genes 0.000 claims 63
- 239000002773 nucleotide Substances 0.000 claims 30
- 125000003729 nucleotide group Chemical group 0.000 claims 30
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims 18
- 239000000523 sample Substances 0.000 claims 15
- 102100025588 Calcitonin gene-related peptide 1 Human genes 0.000 claims 11
- 208000002193 Pain Diseases 0.000 claims 8
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims 7
- 239000005557 antagonist Substances 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 239000002336 ribonucleotide Substances 0.000 claims 6
- 108091028664 Ribonucleotide Proteins 0.000 claims 5
- 239000005547 deoxyribonucleotide Substances 0.000 claims 5
- 238000001514 detection method Methods 0.000 claims 5
- 125000002652 ribonucleotide group Chemical group 0.000 claims 5
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- 208000005298 acute pain Diseases 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 101001081479 Homo sapiens Islet amyloid polypeptide Proteins 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 230000036592 analgesia Effects 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 229960005181 morphine Drugs 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000004614 tumor growth Effects 0.000 claims 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 polyoxypropylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP2012/000089 | 2012-01-10 | ||
| PCT/EP2012/000089 WO2012095303A1 (en) | 2011-01-10 | 2012-01-10 | Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same |
| EP12000105 | 2012-01-10 | ||
| EP12000105.2 | 2012-01-10 | ||
| PCT/EP2013/000055 WO2013104539A1 (en) | 2012-01-10 | 2013-01-10 | Nucleic acids specifically binding cgrp |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015506174A JP2015506174A (ja) | 2015-03-02 |
| JP2015506174A5 true JP2015506174A5 (enExample) | 2016-03-03 |
Family
ID=48781062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551569A Pending JP2015506174A (ja) | 2012-01-10 | 2013-01-10 | Ｃｇｒｐに特異的に結合する核酸 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9163243B2 (enExample) |
| EP (1) | EP2802659A1 (enExample) |
| JP (1) | JP2015506174A (enExample) |
| KR (1) | KR20140111704A (enExample) |
| CN (1) | CN104136612A (enExample) |
| AU (1) | AU2013209130A1 (enExample) |
| BR (1) | BR112014016939A2 (enExample) |
| CA (1) | CA2860809A1 (enExample) |
| HK (1) | HK1198370A1 (enExample) |
| IL (1) | IL233515A0 (enExample) |
| MX (1) | MX2014008456A (enExample) |
| RU (1) | RU2014132706A (enExample) |
| SG (1) | SG11201403769YA (enExample) |
| WO (1) | WO2013104539A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014016877B1 (pt) | 2012-01-10 | 2022-03-15 | Aptarion Biotech Ag | Molécula de l-ácido nucleico capaz de se ligar a c5a humana, seus usos, bem como composição farmacêutica, complexo, método para a seleção de um antagonista de uma atividade mediada por c5a e kit para a detecção de c5a |
| AU2015230933B2 (en) | 2014-03-21 | 2020-08-13 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| JP6584868B2 (ja) * | 2015-02-25 | 2019-10-02 | 学校法人 関西大学 | ゲル素材及びその製造方法 |
| US20170088612A1 (en) * | 2015-09-24 | 2017-03-30 | Teva Pharmaceuticals International Gmbh | Preventing, treating, and reducing (persistent) post-traumatic headache |
| ES2607639B1 (es) | 2015-09-30 | 2018-02-28 | Urquima, S.A | Sal de ácido maleico de un intermedio de silodosina |
| KR20220031944A (ko) | 2016-09-23 | 2022-03-14 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
| WO2020098968A1 (en) | 2018-11-12 | 2020-05-22 | Aptarion Biotech Ag | Cxcl8 binding nucleic acids |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011020A (en) | 1990-06-11 | 2000-01-04 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligand complexes |
| US5840867A (en) | 1991-02-21 | 1998-11-24 | Gilead Sciences, Inc. | Aptamer analogs specific for biomolecules |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6682886B1 (en) | 1994-04-28 | 2004-01-27 | Gilead Sciences, Inc. | Bivalent binding molecules of 7 transmembrane G protein-coupled receptors |
| JPH10504457A (ja) | 1994-08-16 | 1998-05-06 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | カルシトニンレセプター |
| WO1996038579A1 (en) | 1995-06-02 | 1996-12-05 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to growth factors |
| US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6652886B2 (en) | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
| RU2180311C1 (ru) | 2001-07-05 | 2002-03-10 | Мешалкин Георгий Алексеевич | Защитная пробка |
| ES2346640T4 (es) | 2001-10-26 | 2011-04-26 | Noxxon Pharma Ag | Ácido l-nucleico modificado. |
| EP1306382A1 (de) | 2001-10-26 | 2003-05-02 | Noxxon Pharma AG | Modifizierte L-Nukleinsäure |
| EP2138575B8 (en) | 2002-02-20 | 2013-07-24 | Mersana Therapeutics, Inc. | Conjugates comprising a biodegradable polymer and uses therefor |
| US7879991B2 (en) | 2002-05-06 | 2011-02-01 | Noxxon Pharma Ag | CGRP binding nucleic acids |
| KR20060015505A (ko) | 2003-04-13 | 2006-02-17 | 엔존 파마슈티컬즈, 인코포레이티드 | 올리고뉴클레오타이드 전구약물 |
| GB0314472D0 (en) | 2003-06-20 | 2003-07-23 | Warwick Effect Polymers Ltd | Polymer |
| US20090281296A1 (en) | 2004-02-09 | 2009-11-12 | Supramol Parenteral Colloid Gmbh | Process for the production of conjugates from polysaccharides and polynucelotides |
| ES2741524T3 (es) | 2004-03-23 | 2020-02-11 | Ascendis Pharma Gmbh | Profármaco polimérico con un enlazador autoinmolador |
| WO2006052790A2 (en) | 2004-11-05 | 2006-05-18 | The Children's Hospital Of Philadelphia | Biodegradable linkers for molecular therapies |
| CA2607185A1 (en) * | 2005-05-04 | 2006-11-09 | Noxxon Pharma Ag | Intracellular active agents |
| CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
| EP2407558A1 (en) | 2006-10-31 | 2012-01-18 | Noxxon Pharma AG | Methods for the detection of a single- or double-stranded nucleic acid molecule |
| WO2011131371A1 (en) | 2010-04-21 | 2011-10-27 | Noxxon Pharma Ag | Lipid binding nucleic acids |
| KR20140026357A (ko) * | 2011-01-10 | 2014-03-05 | 녹손 파르마 아게 | 목표 분자에 결합력을 갖는 핵산 및 이를 제조하는 방법 |
-
2013
- 2013-01-10 SG SG11201403769YA patent/SG11201403769YA/en unknown
- 2013-01-10 WO PCT/EP2013/000055 patent/WO2013104539A1/en not_active Ceased
- 2013-01-10 BR BR112014016939A patent/BR112014016939A2/pt not_active IP Right Cessation
- 2013-01-10 AU AU2013209130A patent/AU2013209130A1/en not_active Abandoned
- 2013-01-10 RU RU2014132706A patent/RU2014132706A/ru not_active Application Discontinuation
- 2013-01-10 CN CN201380009019.6A patent/CN104136612A/zh active Pending
- 2013-01-10 EP EP13700455.2A patent/EP2802659A1/en not_active Withdrawn
- 2013-01-10 HK HK14111873.3A patent/HK1198370A1/xx unknown
- 2013-01-10 US US14/371,210 patent/US9163243B2/en not_active Expired - Fee Related
- 2013-01-10 JP JP2014551569A patent/JP2015506174A/ja active Pending
- 2013-01-10 CA CA2860809A patent/CA2860809A1/en not_active Abandoned
- 2013-01-10 MX MX2014008456A patent/MX2014008456A/es unknown
- 2013-01-10 KR KR1020147022328A patent/KR20140111704A/ko not_active Withdrawn
-
2014
- 2014-07-03 IL IL233515A patent/IL233515A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015506174A5 (enExample) | ||
| JP2015509705A5 (enExample) | ||
| JP2013524792A5 (enExample) | ||
| RU2014132706A (ru) | Нуклеиновые кислоты, специфически связывающие cgrp | |
| RU2014132708A (ru) | НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ | |
| Cunha-Neto et al. | Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas' disease cardiomyopathy | |
| Englund et al. | Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds | |
| Handl et al. | Synthesis and evaluation of bivalent NDP-α-MSH (7) peptide ligands for binding to the human melanocortin receptor 4 (hMC4R) | |
| Haskell-Luevano et al. | Biological and conformational examination of stereochemical modifications using the template melanotropin peptide, Ac-Nle-c [Asp-His-Phe-Arg-Trp-Ala-Lys]-NH2, on human melanocortin receptors | |
| JP2009543567A5 (enExample) | ||
| JP2014533098A5 (enExample) | ||
| CN109439664A (zh) | 结合il-6的适体及其在治疗或诊断il-6介导的疾患中的用途 | |
| RU2008136907A (ru) | Нуклеиновые кислоты, связывающиеся с мср-1 | |
| JP2020533413A (ja) | ベータ−カテニンの機能を調節する薬剤及びその方法 | |
| Zhang et al. | NMR and modeling studies of a synthetic extracellular loop II of the κ opioid receptor in a DPC micelle | |
| Todorov et al. | Synthesis, characterization and nociceptive screening of new VV-hemorphin-5 analogues | |
| Li et al. | Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin? | |
| Kokko et al. | In vitro analysis of stable, receptor-selective neurotensin [8− 13] analogues | |
| JP6041373B2 (ja) | ＴＮＦ−αに結合するアプタマー分子 | |
| EP4317456B1 (en) | Piezo type mechanosensitive ion channel component 1 (piezo1) variants and uses thereof | |
| Vaszar et al. | Longitudinal transcriptional analysis of developing neointimal vascular occlusion and pulmonary hypertension in rats | |
| Park et al. | Synthesis and biological evaluation of peptide-derived TSLP inhibitors | |
| US9150634B2 (en) | Epitopes of the human PDGF receptor able to bind human auto-antibodies, antibodies and uses thereof | |
| Singh et al. | Synthesis, biophysical, and pharmacological evaluation of the melanocortin agonist AST3-88: Modifications of peptide backbone at Trp 7 position lead to a potent, selective, and stable ligand of the melanocortin 4 receptor (MC4R) | |
| Todorovic et al. | Discovery of melanocortin ligands via a double simultaneous substitution strategy based on the Ac-His-DPhe-Arg-Trp-NH2 template |